Mar 10, 2025
For nearly three decades, Genentech has been the sole provider of an approved medication for acute stroke treatment. On 03 March 2025, the Roche subsidiary expanded its stroke treatment portfolio with FDA approval for TNKase (tenecteplase). TNKase (tenecteplase) is a thrombolytic, clot-dissolving tis...
Read More...
Mar 06, 2023
Acute ischemic stroke, contributing up to 80% of all stroke cases, is among the leading causes of death and morbidity, leaving around 50% of stroke survivors disabled worldwide. It is caused due to the blockage of an artery resulting in reduced blood flow to the brain that damages and interrupts brain functions. Hi...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper